We are live on !
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter Est. Return
+24.25%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.59B
AUM Growth
+$706M
(+18%)
Cap. Flow
-$31.5M
Cap. Flow % of AUM
Cap. Flow %
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
73.61%
Holding
44
New
6
Increased
8
Reduced
2
Closed
3
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$53.1M |
| 2 |
Allogene Therapeutics
ALLO
|
+$41M |
| 3 |
NewAmsterdam Pharma
NAMS
|
+$37.7M |
| 4 |
Achieve Life Sciences
ACHV
|
+$36.3M |
| 5 |
Kailera Therapeutics
KLRA
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$133M |
| 2 |
KalVista Pharmaceuticals
KALV
|
+$100M |
| 3 |
Revolution Medicines
RVMD
|
+$65.7M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$42.5M |
| 5 |
Trevi Therapeutics
TRVI
|
+$1.45K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.77% |
| 2 | Miscellaneous | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Zai Lab
ZLAB
$2.7B
| $36.1M | 0.79% |
1,902,320
| – | – |
2025 Q1
5 quarters
|
|
27
MannKind Corp
MNKD
$1.03B
| $28.1M | 0.61% |
6,600,000
+700,000
| +12% | +$2.27M |
2025 Q4
2 quarters
|
|
28
Design Therapeutics
DSGN
$641M
| $26.2M | 0.57% |
+1,809,854
| New | +$22.6M |
2026 Q2
0 quarters
|
|
29
Aclaris Therapeutics
ACRS
$552M
| $26.1M | 0.57% |
4,925,374
| – | – |
2026 Q1
1 quarter
|
|
30
Shattuck Labs
STTK
$551M
| $26M | 0.57% |
+3,750,000
| New | +$23.4M |
2026 Q2
0 quarters
|
|
|
31
Kailera Therapeutics
KLRA
$1.67B
| $24.2M | 0.53% |
+1,100,000
| New | +$24.2M |
2026 Q2
0 quarters
|
|
32
Monte Rosa Therapeutics
GLUE
$925M
| $24.2M | 0.53% |
1,000,000
| – | – |
2026 Q1
1 quarter
|
|
33
Lexeo Therapeutics
LXEO
$230M
| $22.5M | 0.49% |
4,824,725
+400,000
| +9% | +$2.16M |
2024 Q3
7 quarters
|
|
34
Relay Therapeutics
RLAY
$3.98B
| $19M | 0.41% |
+1,015,693
| New | +$14.7M |
2026 Q2
0 quarters
|
|
35
Evolus
EOLS
$463M
| $18.3M | 0.4% |
2,630,665
| – | – |
2025 Q2
4 quarters
|
|
36
Immunocore
IMCR
$1.6B
| $15.4M | 0.34% |
484,782
| – | – |
2024 Q2
8 quarters
|
|
37
Valneva
VALN
$499M
| $12M | 0.26% |
2,291,666
| – | – |
2025 Q2
4 quarters
|
|
|
38
NewAmsterdam Pharma Warrant
NAMSW
$42.6M
| $10.7M | 0.23% |
500,333
| – | – |
2022 Q4
14 quarters
|
|
39
Autolus Therapeutics
AUTL
$410M
| $7.12M | 0.16% |
4,447,910
| – | – |
2022 Q1
17 quarters
|
|
40
Xilio Therapeutics
XLO
$49.8M
| $4.05M | 0.09% |
422,505
| – | – |
2025 Q4
2 quarters
|
|
41
iBio
IBIO
$46.2M
| $3.42M | 0.07% |
1,953,467
| – | – |
2025 Q4
2 quarters
|
|
|
42
Agios Pharmaceuticals
AGIO
$2.21B
| – | – |
-1,256,080
| Closed | -$42.5M | – |
|
|
43
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-4,961,108
| Closed | -$100M | – |
|
|
44
Revolution Medicines
RVMD
$40.1B
| – | – |
-675,686
| Closed | -$65.7M | – |
|
Similar funds
BWA
Frazier Life Sciences Management's Q2 2026 Portfolio in Review
As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M.
- Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
- Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
- Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $100M.
- Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
- Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
- Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.